[ad_1]
SALT LAKE CITY, May 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today presented data demonstrating the health and economic benefit of the PreTRM® test-and-treat strategy. The presentation titled “Clinical and Economic Utility of a Proteomic Biomarker Preterm Birth Predictor: Analysis of a Large and Diverse Pregnancy Cohort” was given by lead author Julja Burchard today at the ISPOR (The Professional Society for Health Economics and Outcomes Research) 2022 international conference in Washington DCSession 5 from 9:00-12:45pm.
- The study, using patient data from the Multicenter Assessment of Spontaneous Preterm Birth Risk Predictor Study (TREETOP; NCT02787213), modeled the effects of two test-and-treat intervention strategies (case management alone and a multi-modal strategy of case management together with progesterone treatment) in subjects determined to be at higher risk of spontaneous preterm birth by their measured PreTRM® Test results. The analysis demonstrated that with case management alone:
o Neonatal and maternal length of hospital stay was reduced significantly by 22% and 8.5%, respectively.
o Moderate-to-severe neonatal morbidity and mortality fell significantly by 29%.
o Neonatal costs associated with hospital stay decreased by 16% after intervention cost but did not reach significance.
o Adding pharmacological treatment in …
Full story available on Benzinga.com
[ad_2]
Source link
